CX NEWS
Low early mortality and high technical success for novel thoracic stent graft
A physician-sponsored investigational device exemption trial on thoracic endovascular aortic repair (TEVAR) using a new thoracic stent graft (Valiant thoracoabdominal aortic aneurysm stent graft, Medtronic), along with its initial 30-day data, was revealed at [...]
First case experience presented with next generation conformable EVAR device
CX delegates were presented data from the first 10 EVAR patients treated using a new conformable device, the Gore Excluder conformable abdominal aortic aneurysm endoprosthesis with active control system, yesterday. Robert Rhee (Brooklyn, New [...]
“Fantastic” live case demonstrates potential value of intravascular lithotripsy
In an exciting session yesterday, the CX audience witnessed the demonstration of a novel treatment strategy with intravascular lithotripsy for calcified arterial stenosis. It will now become a CX tradition to feature live cases [...]
Live cases to illustrate the data: The future of the Charing Cross Symposium
In yesterday’s plenary programmes, the future of the Charing Symposium was launched with the initiation of live case demonstrations to illustrate key data discussed on the programme. This year, both the Thoracic Aortic programme [...]
STEP seeks to advance patient safety after TEVAR
Stroke is a major concern following TEVAR (thoracic endovascular aortic repair) and Charing Cross delegates heard the results from a collaborative study that pooled practice data from a number of high-volume centres in order [...]
Ulf Teichgräber discusses the EffPAC trial 12-month results which were presented for the first time at CX 2018
Ulf Teichgräber discusses the EffPAC trial 12-month results which were presented for the first time at CX 2018 Ulf Teichgräber, Jena, Germany